

Benjamin Z Leder

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3377760/publications.pdf>

Version: 2024-02-01

71
papers

5,795
citations

126708

33
h-index

106150

65
g-index

72
all docs

72
docs citations

72
times ranked

4967
citing authors

#	ARTICLE	IF	CITATIONS
1	Romosozumab and antiresorptive treatment: the importance of treatment sequence. <i>Osteoporosis International</i> , 2022, 33, 1243-1256.	1.3	38
2	Widespread disturbance in extracellular matrix collagen biomarker responses to teriparatide therapy in osteogenesis imperfecta. <i>Bone</i> , 2021, 142, 115703.	1.4	4
3	Bone Mineral Density Response With Denosumab in Combination With Standard or High-Dose Teriparatide: The DATA-HD RCT. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 890-897.	1.8	10
4	Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 938-943.	1.8	29
5	What Else Do We Need? A Commentary on Zoledronate Effects on Cancer and Cardiac Events. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 18-19.	3.1	1
6	Delayed Denosumab Injections and Bone Mineral Density Response: An Electronic Health Record-based Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 1435-1444.	1.8	26
7	Delayed Denosumab Injections and Fracture Risk Among Patients With Osteoporosis. <i>Annals of Internal Medicine</i> , 2020, 173, 516-526.	2.0	65
8	Dose-Response Relationships Between Gonadal Steroids and Bone, Body Composition, and Sexual Function in Aging Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 2779-2788.	1.8	15
9	Effects of Combination Denosumab and High-Dose Teriparatide Administration on Bone Microarchitecture and Estimated Strength: The DATA-HD HR-pQCT Study. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 41-51.	3.1	7
10	Early Effects of Abaloparatide on Bone Formation and Resorption Indices in Postmenopausal Women With Osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 644-653.	3.1	22
11	Efficacy of Zoledronic Acid in Maintaining Areal and Volumetric Bone Density After Combined Denosumab and Teriparatide Administration: DATA-HD Study Extension. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 921-930.	3.1	19
12	Combination and Sequential Osteoanabolic/Antiresorptive Therapy in Osteoporosis Treatment. <i>Contemporary Endocrinology</i> , 2020, , 363-374.	0.3	1
13	Fracture and Bone Mineral Density Response by Baseline Risk in Patients Treated With Abaloparatide Followed by Alendronate: Results From the Phase 3 ACTIVEExtend Trial. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 2213-2219.	3.1	13
14	Comparison of Teriparatide and Denosumab in Patients Switching From Long-Term Bisphosphonate Use. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 5611-5620.	1.8	28
15	Combination denosumab and high dose teriparatide for postmenopausal osteoporosis (DATA-HD): a randomised, controlled phase 4 trial. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 767-775.	5.5	48
16	A Lot of Progress, With More to Be Done: A Response to NIH Pathways to Prevention Report "Research Gaps for Long-Term Drug Therapies for Osteoporotic Fracture Prevention". <i>Journal of Bone and Mineral Research</i> , 2019, 34, 1549-1551.	3.1	4
17	Osteoporosis Treatment: Sequential and Combination Therapy. , 2019, , 281-287.		1
18	Comparison of Denosumab and Bisphosphonates in Patients With Osteoporosis: A Meta-Analysis of Randomized Controlled Trials. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 1753-1765.	1.8	55

#	ARTICLE	IF	CITATIONS
19	Optimizing Sequential and Combined Anabolic and Antiresorptive Osteoporosis Therapy. <i>JBMR Plus</i> , 2018, 2, 62-68.	1.3	58
20	An Essential Warning. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 188-189.	3.1	17
21	Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The Denosumab and Teriparatide Follow-up study (DATA-Follow-up). <i>Bone</i> , 2017, 98, 54-58.	1.4	94
22	Parathyroid Hormone and Parathyroid Hormone-Related Protein Analogs in Osteoporosis Therapy. <i>Current Osteoporosis Reports</i> , 2017, 15, 110-119.	1.5	70
23	Effects of Denosumab and Teriparatide Transitions on Bone Microarchitecture and Estimated Strength: the DATA-Switch HR-pQCT study. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 2001-2009.	3.1	59
24	Effects of Teriparatide, Denosumab, or Both on Spine Trabecular Microarchitecture in DATA-Switch: a Randomized Controlled Trial. <i>Journal of Clinical Densitometry</i> , 2017, 20, 507-512.	0.5	30
25	Letter to the editor in response to the commentary, "Concurrent administration of PTH and antiresorptives: Additive effects or DXA cosmetics. <i>Bone</i> , 2016, 89, 73-74.	1.4	4
26	Response to Therapy With Teriparatide, Denosumab, or Both in Postmenopausal Women in the DATA (Denosumab and Teriparatide Administration) Study Randomized Controlled Trial. <i>Journal of Clinical Densitometry</i> , 2016, 19, 346-351.	0.5	29
27	Gonadal steroid-dependent effects on bone turnover and bone mineral density in men. <i>Journal of Clinical Investigation</i> , 2016, 126, 1114-1125.	3.9	148
28	Comparative Effects of Teriparatide, Denosumab, and Combination Therapy on Peripheral Compartmental Bone Density, Microarchitecture, and Estimated Strength: the DATA-HRpQCT Study. <i>Journal of Bone and Mineral Research</i> , 2015, 30, 39-45.	3.1	121
29	Comparative Resistance to Teriparatide-Induced Bone Resorption With Denosumab or Alendronate. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 2718-2723.	1.8	7
30	Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. <i>Lancet</i> , The, 2015, 386, 1147-1155.	6.3	403
31	Insulin secretion and sensitivity in healthy adults with low vitamin D are not affected by high-dose ergocalciferol administration: a randomized controlled trial. <i>American Journal of Clinical Nutrition</i> , 2015, 102, 385-392.	2.2	33
32	Combination Osteoporosis Therapy with Parathyroid Hormone. , 2015, , 853-863.		1
33	Effects of Abaloparatide, a Human Parathyroid Hormone-Related Peptide Analog, on Bone Mineral Density in Postmenopausal Women with Osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 697-706.	1.8	209
34	FSH Suppression Does Not Affect Bone Turnover in Eugonadal Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 2510-2515.	1.8	19
35	Effects of Escitalopram on Markers of Bone Turnover: A Randomized Clinical Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E1732-E1737.	1.8	20
36	Teriparatide (PTH 1-34) Treatment Increases Peripheral Hematopoietic Stem Cells in Postmenopausal Women. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 1380-1386.	3.1	27

#	ARTICLE	IF	CITATIONS
37	Two Years of Denosumab and Teriparatide Administration in Postmenopausal Women With Osteoporosis (The DATA Extension Study): A Randomized Controlled Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 1694-1700.	1.8	231
38	Gonadal Steroids and Body Composition, Strength, and Sexual Function in Men. <i>New England Journal of Medicine</i> , 2013, 369, 1011-1022.	13.9	621
39	Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. <i>Lancet</i> , The, 2013, 382, 50-56.	6.3	384
40	Medicines and Bone Loss. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 33A-34A.	1.8	3
41	Sarcopenia During Androgen-Deprivation Therapy for Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 3271-3276.	0.8	148
42	Randomized Trial Assessing the Effects of Ergocalciferol Administration on Circulating FGF23. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 624-631.	2.2	45
43	Denosumab and changes in bone turnover markers during androgen deprivation therapy for prostate cancer. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 2827-2833.	3.1	28
44	Acute Decline in Serum Sclerostin in Response to PTH Infusion in Healthy Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, E1848-E1851.	1.8	50
45	Androgens and the Skeleton " Humans. , 2010, , 319-334.		0
46	El cáncer de mama y la pérdida de masa ósea. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, E2-E2.	1.8	0
47	Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer. <i>New England Journal of Medicine</i> , 2009, 361, 745-755.	13.9	1,010
48	Relation between Serum Testosterone, Serum Estradiol, Sex Hormone-Binding Globulin, and Geometrical Measures of Adult Male Proximal Femur Strength. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 853-860.	1.8	30
49	Effects of Teriparatide Treatment and Discontinuation in Postmenopausal Women and Eugonadal Men with Osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 2915-2921.	1.8	115
50	Effects of aromatase inhibition in hypogonadal older men: a randomized, double-blind, placebo-controlled trial. <i>Clinical Endocrinology</i> , 2009, 70, 116-123.	1.2	57
51	Effects of hPTH(1-34) Infusion on Circulating Serum Phosphate, 1,25-Dihydroxyvitamin D, and FGF23 Levels in Healthy Men. <i>Journal of Bone and Mineral Research</i> , 2009, 24, 1681-1685.	3.1	71
52	Effects of Aromatase Inhibition on Bone Mineral Density and Bone Turnover in Older Men with Low Testosterone Levels. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 4785-4792.	1.8	122
53	Effects of Teriparatide Retreatment in Osteoporotic Men and Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 2495-2501.	1.8	72
54	Correlations between Serum Testosterone, Estradiol, and Sex Hormone-Binding Globulin and Bone Mineral Density in a Diverse Sample of Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 2135-2141.	1.8	79

#	ARTICLE	IF	CITATIONS
55	Is parathyroid hormone (1 α -84) a safe and effective treatment for postmenopausal osteoporosis?. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2007, 3, 746-747.	2.9	0
56	Racial and Ethnic Differences in Bone Turnover Markers in Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 3453-3457.	1.8	33
57	Gonadal steroids and bone metabolism in men. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2007, 14, 241-246.	1.2	18
58	Effects of gonadal steroid withdrawal on serum phosphate and FGF-23 levels in men. <i>Bone</i> , 2007, 40, 913-918.	1.4	33
59	Testosterone, estradiol and aromatase inhibitor therapy in elderly men. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2007, 106, 162-167.	1.2	7
60	Effects of Selective Testosterone and Estradiol Withdrawal on Skeletal Sensitivity to Parathyroid Hormone in Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 1069-1075.	1.8	31
61	Effects of Teriparatide, Alendronate, or Both on Bone Turnover in Osteoporotic Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 2882-2887.	1.8	130
62	Effect of aromatase inhibition on lipids and inflammatory markers of cardiovascular disease in elderly men with low testosterone levels. <i>Clinical Endocrinology</i> , 2005, 62, 228-235.	1.2	40
63	Effect of aromatase inhibition on bone metabolism in elderly hypogonadal men. <i>Osteoporosis International</i> , 2005, 16, 1487-1494.	1.3	43
64	Effects of Aromatase Inhibition in Elderly Men with Low or Borderline-Low Serum Testosterone Levels. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 1174-1180.	1.8	142
65	Differential Effects of Androgens and Estrogens on Bone Turnover in Normal Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 204-210.	1.8	265
66	Authors'™ Response: Androgens, Estrogens, and Bone Turnover in Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 2352-2353.	1.8	8
67	Effects of Oral Androstenedione Administration on Serum Testosterone and Estradiol Levels in Postmenopausal Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 5449-5454.	1.8	36
68	Metabolism of Orally Administered Androstenedione in Young Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 3654-3658.	1.8	36
69	Effects of Gonadal Steroid Suppression on Skeletal Sensitivity to Parathyroid Hormone in Men¹. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 511-516.	1.8	54
70	Oral Androstenedione Administration and Serum Testosterone Concentrations in Young Men. <i>JAMA - Journal of the American Medical Association</i> , 2000, 283, 779.	3.8	116
71	Gonadal Steroids and the Skeleton in Men: Clinical Aspects. , 0, , 393-412.		2